iC9.GD2.CAR.IL-15 T-cells Therapy

N/A

Report date: 2022/03/15 16:20:33

Base Information

Drug NameiC9.GD2.CAR.IL-15 T-cells Therapy
Drug Alias NameCAR T-Cells Targeting the GD2 With IL-15+iCaspase9
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionDisialoganglioside GD2 inhibitors
TargetsDisialoganglioside GD2
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUnc Lineberger Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesUnc Lineberger Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A